Table 1 Comparison of clinical data and thyroid hormone levels in T2DM patients with or without NAFLD

Sex (male/female)

101/139

162/184

0.257

Age (years)

62(54–70)

58.5(52–66)

0.002

Diabetes course (years)

10(5–14.75)

7(3–12)

0.004

Duration of treatment (years)

9(3–14)

7(1–12)

0.013

BMI (kg/m²)

23.81 ± 3.20

26.25 ± 3.37

0.000

Systolic pressure(mmHg)

132(122–142)

133(124–148)

0.280

Diastolic pressure(mmHg)

80(74–86)

82(76–90)

0.001

Waistline(cm)

88.22 ± 10.51

94.46 ± 9.43

0.000

Hipline (cm)

97(92–102)

101(96–105)

0.000

Waist hip ratio (WHR)

0.91(0.87–0.96)

0.93(0.90–0.97)

0.000

NFS

− 0.2479 ± 1.0663

−0.4283 ± 1.0132

0.038

ALT(U/L)

16(12–21)

20(15–30)

0.000

AST(U/L)

16(14–19)

17(15–22)

0.000

AST/ALT

1.00(0.82–1.25)

0.85(0.68–1.01)

0.000

γ- GGT (U/L)

18(14–26)

26(19–39)

0.000

AKP(U/L)

91.00(74.00–113.00)

92.00(75.75–114.00)

0.291

FBG (mmol/L)

7.11(5.75–10.41)

7.70(6.42–9.86)

0.032

TG (mmol/L)

1.16(0.84–1.64)

1.70(1.26–2.50)

0.000

TC (mmol/L)

4.51 ± 0.99

4.64 ± 0.98

0.107

HDL (mmol/L)

1.19(1.01–1.48)

1.07(0.92–1.31)

0.000

LDL (mmol/L)

2.65(2.10–3.32)

2.78(2.22–3.32)

0.276

APO-A1(g/L)

1.30 ± 0.25

1.25 ± 0.25

0.025

APO-B(g/L)

0.87 ± 0.23

0.94 ± 0.22

0.000

FT3(pmol/L)

3.95 ± 0.51

4.04 ± 0.47

0.021

FT4(pmol/L)

13.39 ± 1.53

13.04 ± 1.49

0.007

TT3(nmol/L)

1.35(1.21–1.52)

1.39(1.26–1.55)

0.032

TT4(nmol/L)

87.11 ± 15.96

85.84 ± 15.77

0.341

FT3/FT4

0.297 ± 0.044

.313 ± 0.045

0.000

TSH (uIU/L)

2.0201(1.4275–2.9372)

2.0534(1.3637–2.8333)

0.708

HOMA-IR (CP)

2.8429(2.2891–3.4687)

3.4185(2.7337–4.3036)

0.000

FCP (ng/mL)

1.47(0.99–2.03)

2.15(1.43–2.77)

0.000

HBA1C (%)

7.70(6.73–9.90)

8.00(6.80–9.63)

0.503

FLI

23.31(10.51–41.11)

53.35(34.53–71.37)

0.000